Legal Claim Assistant

Biozorb

The Biozorb breast marker lawsuit is a significant legal development concerning a medical device used to mark tissue for post-operative radiation in breast cancer patients. Plaintiffs allege that the Biozorb marker, manufactured by Hologic, failed to dissolve as intended, leading to complications such as pain, infection, device migration, and erosion.

These lawsuits gained momentum after the FDA issued a Class 1 recall for Biozorb markers in October 2024, the most serious type of recall indicating a risk of serious injury or death. The FDA’s warning letter to Hologic in December 2024 highlighted concerns about manufacturing processes, quality control, and failure to report adverse events adequately.